In the Spotlight...
CAR T cells based on fully human T cell receptor-mimetic antibodies exhibit potent antitumor activity in vivo
A lupus-derived autoantibody that binds to intracellular RNA activates cGAS-mediated tumor immunity and can deliver RNA into cells
Embryonic reprogramming of the tumor vasculature reveals targets for cancer therapy
New soluble CSF-1R-dimeric mutein with enhanced trapping of both CSF-1 and IL-34 reduces suppressive tumor-associated macrophages in pleural mesothelioma
Previous Digests
From TCRs to immunotherapy targets: detection of antigens in pediatric brain tumors
March 26, 2025
Few targetable antigens are known for pediatric brain tumors, which have limited immunotherapy development. Based on this pressing need, Raphael et al. analyzed the TCR repertoires of tumor-infiltrating T cells (TILs), and predicted antigens based on these repertoires. Their...
Finding the right combination: new insights in anti-PD-1 plus anti-CTLA-4 or anti-LAG3
March 19, 2025
Treatment with checkpoint blockades alone or in various combinations can induce strong antitumor responses, but identifying which treatment or combination will work best for each individual patient is still a challenge. In work recently published in Cancer Cell, Li...
Tumoral RNA splicing: source of neoantigens for off-the-shelf therapies?
March 12, 2025
Immunotherapies targeting tumor-specific antigens (TSAs) derived from somatic mutations have limited potential in tumors with low mutational burdens. A recently discovered source of TSAs are cancer-specific splicing events (neojunctions; NJs), which have the potential to induce CD8+ T cell...
Watch ACIR in action
In November 2019, ACIR received the Visionary Award from the Cambridge Chamber of Commerce.
Watch the 3-minute video explaining ACIR's mission and goal:
In September 2020, ACIR was featured in the documentary The American Dream on Bloomberg TV.
Watch the 6-minute segment on the story behind your favorite digest here:
About ACIR
ACIR's mission is to fast-track cancer immunotherapy research by helping researchers stay on top of the new literature in this fast-moving and multifaceted field, fostering their creativity and productivity in bringing us ever closer to curing this deadly disease.
Ed Fritsch
Ute Burkhardt
Lauren Hitchings
Gaelle Llambi
Maartje Wouters
Alex Najibi
Katherine J. Turner
Stan Wolf
Paula Hochman
Shishir Pant
Nathan Suek
Morgan Janes
TESTIMONIALS
I am pleased to voice my support for the mission of ACIR to keep cancer immunotherapy researchers up to date with the current advancements in the field. Given the magnitude of new information emerging from this field, I particularly appreciate their efforts to both identify and highlight the key advancements each week and to distill the new information to key take-away points that can be easily grasped.
Professor of Medicine, Harvard Medical School; Director, MGH Center for Cancer Immunology; Institute Member, Broad Institute of Harvard and MIT
Current Sponsors
